Abbott Announces Cologuard Recommended as Preferred Colorectal Cancer Screening
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 3 days ago
0mins
Abbott announced that the American Cancer Society has released updated colorectal cancer screening guidelines that reaffirm Cologuard and Cologuard Plus as preferred noninvasive screening options for adults age 45 and older who are at average risk for CRC. Both tests are used at a three-year interval.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ABT?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ABT
Wall Street analysts forecast ABT stock price to rise
19 Analyst Rating
17 Buy
2 Hold
0 Sell
Strong Buy
Current: 86.300
Low
136.00
Averages
148.11
High
169.00
Current: 86.300
Low
136.00
Averages
148.11
High
169.00
About ABT
Abbott Laboratories is a global healthcare company. The Company’s principal business is the discovery, development, manufacture, and sale of a broad and diversified line of healthcare products. Its segments include Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. Established Pharmaceutical Products segment is engaged in the international sales of a broad line of branded generic pharmaceutical products. Diagnostic Products segment is involved in the worldwide sales of diagnostic systems and tests for blood banks, hospitals, commercial laboratories and alternate-care testing sites. Nutritional Products segment is engaged in the worldwide sales of a broad line of adult and pediatric nutritional products. Medical Devices segment is involved in the worldwide sales of rhythm management, electrophysiology, heart failure, vascular, structural heart, neuromodulation and diabetes care products. It serves people in more than 160 countries.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Abbott Secures FDA and EU Approval for Next-Gen AI Imaging Software
- Technological Innovation: Abbott's Ultreon 3.0 software has received FDA and CE Mark approval, becoming the first optical coherence tomography system in the US and Europe to integrate high-resolution coronary artery plaque imaging with AI-automated analysis, marking a significant advancement in medical imaging technology.
- Real-Time Analysis Capability: The platform utilizes AI to analyze OCT images in real time, assisting physicians in making faster and more precise decisions during stent placements, thereby significantly enhancing the efficiency of treating blocked coronary arteries and improving patient blood flow restoration.
- Risk Reduction: Compared to traditional intravascular ultrasound (IVUS), Ultreon 3.0 provides higher-resolution images while requiring little to no contrast dye, thus reducing the risk of contrast-induced kidney complications in certain patients, enhancing patient safety.
- Market Potential: As a diversified medical technology company, Abbott's extensive portfolio in diagnostics, medical devices, and nutritional products positions it strongly in the rapidly evolving healthcare market, especially as AI technologies become increasingly prevalent.
See More
Abbott Launches First Dual Glucose-Ketone Monitoring Biowearable
- Innovative Monitoring Technology: Abbott's Libre Duo system has received CE Mark approval, marking the first dual glucose-ketone monitoring technology that provides real-time data updates every minute, aiding diabetes patients in better health management and reducing the risk of diabetic ketoacidosis (DKA).
- Market Demand Response: Designed for both adults and children, the Libre Duo offers up to 15 days of wear, while the Libre Duo 10 Day is suitable for children aged 2 and older, addressing the needs of various age groups and significantly enhancing market competitiveness.
- Integration with Digital Health Ecosystem: The Libre Duo system seamlessly integrates with Abbott's digital health ecosystem, allowing users to share data with caregivers, enhancing interaction between patients and healthcare providers, and improving overall care quality.
- Addressing Rising DKA Issues: Research indicates that DKA hospitalization rates have increased by approximately 55% over the past decade, and the launch of the Libre Duo system aims to help patients take timely action through early ketone monitoring, thereby reducing DKA incidence and improving diabetes management outcomes.
See More
Abbott Launches New Colorectal Cancer Screening Solutions
- Guideline Update: The American Cancer Society's updated colorectal cancer screening guidelines reaffirm Cologuard® and Cologuard Plus® as preferred noninvasive options for adults aged 45 and older at average risk, which is expected to drive increased screening participation and improve early detection rates.
- Outstanding Detection Performance: Cologuard Plus detects 95% of colorectal cancers with 94% specificity in the U.S. screening population, significantly reducing unnecessary follow-up colonoscopies and enhancing patient confidence in screening results, which may lead to better treatment outcomes.
- Market Expansion Potential: Abbott plans to launch a blood-based test pending FDA approval, aimed at attracting individuals who decline other screening methods, thereby expanding the reach of colorectal cancer screening and further solidifying its market position in noninvasive screening.
- Patient Navigation Support: Cologuard tests, supported by a robust patient navigation program, have achieved up to 77% nationwide colorectal cancer screening participation, driving significant growth from 2018 to 2021, highlighting their strategic importance in improving patient screening experiences and outcomes.
See More
American Cancer Society Updates Colorectal Cancer Screening Guidelines
- Guideline Update: The American Cancer Society (ACS) has updated its colorectal cancer (CRC) screening guidelines, reaffirming Cologuard® and Cologuard Plus® as preferred noninvasive screening options for adults aged 45 and older at average risk, which is expected to drive increased screening participation and improve early detection and cure rates.
- Outstanding Test Performance: Cologuard Plus detects 95% of colorectal cancers with 94% specificity in the U.S. screening population, significantly reducing unnecessary follow-up colonoscopies and enhancing confidence among patients and providers, thereby promoting wider adoption of screening.
- Market Expansion Potential: Abbott plans to launch a blood-based test pending FDA approval, complementing its existing Cologuard portfolio to create a comprehensive CRC screening solution aimed at attracting individuals who decline other screening methods, thus expanding market coverage and increasing screening participation.
- Patient Navigation Support: Abbott's well-established patient navigation support and commercial infrastructure will ensure the reliability and seamless experience of the Cologuard products, which is expected to further enhance patient adherence to screening and satisfaction, contributing to lower incidence and mortality rates of colorectal cancer.
See More
Warren Buffett's Long-Term Investment Advice
- AbbVie's Strong Growth: AbbVie (ABBV), a leading pharmaceutical company, boasts multiple blockbuster drugs and strong growth potential, particularly with its autoimmune drugs Skyrizi and Rinvoq, which are expected to drive sustained growth over the next decade; despite Humira losing patent protection, the company has maintained stability through R&D investments and strategic acquisitions.
- Enterprise Products Partners' Stable Returns: Enterprise Products Partners (EPD) is a key player in the North American midstream energy market, operating over 50,000 miles of pipelines with a distribution yield of 5.5%, having increased its distribution for 27 consecutive years, demonstrating resilience and stability in a volatile energy sector.
- NextEra Energy's Renewable Leadership: NextEra Energy (NEE), the largest utility company globally, anticipates a 10% dividend increase this year, aiming for an 8% annual growth in adjusted earnings per share by 2035, showcasing its strong potential in renewable energy and battery storage.
- AI-Driven Market Opportunities: Both Enterprise Products Partners and NextEra Energy are poised to benefit from the increasing demand for natural gas and renewable energy driven by the growing need for power in data centers, with NextEra's planned $66.8 billion acquisition of Dominion Energy further solidifying its position in rapidly expanding markets.
See More
AbbVie and Two Dividend Kings Show Strong Prospects
- AbbVie's Growth Potential: AbbVie (NYSE: ABBV), a leading pharmaceutical company, boasts multiple blockbuster drugs and has around 60 programs in mid-to-late stage clinical trials, indicating strong growth prospects over the next decade, particularly with its autoimmune disease drugs Skyrizi and Rinvoq.
- Enterprise Products Partners' Stable Returns: Enterprise Products Partners (NYSE: EPD) is a top player in the North American midstream energy market, operating over 50,000 miles of pipelines with a distribution yield of 5.5%, having increased its distribution for 27 consecutive years, showcasing robust cash flow resilience and expected growth from rising natural gas demand.
- NextEra Energy's Acquisition Plans: As the largest utility company globally, NextEra Energy (NYSE: NEE) plans to acquire Dominion Energy for approximately $66.8 billion, which is expected to strengthen its leadership in renewable energy and battery storage, with dividends projected to grow by about 10% this year.
- AI-Driven Market Opportunities: With the increasing demand for power from data centers, both AbbVie and Enterprise Products Partners are poised to benefit from the AI technology boom, which is expected to drive business growth and enhance their competitive positions in the market.
See More
Abbott Secures FDA and EU Approval for Next-Gen AI Imaging Software
- Technological Innovation: Abbott's Ultreon 3.0 software has received FDA and CE Mark approval, becoming the first optical coherence tomography system in the US and Europe to integrate high-resolution coronary artery plaque imaging with AI-automated analysis, marking a significant advancement in medical imaging technology.
- Real-Time Analysis Capability: The platform utilizes AI to analyze OCT images in real time, assisting physicians in making faster and more precise decisions during stent placements, thereby significantly enhancing the efficiency of treating blocked coronary arteries and improving patient blood flow restoration.
- Risk Reduction: Compared to traditional intravascular ultrasound (IVUS), Ultreon 3.0 provides higher-resolution images while requiring little to no contrast dye, thus reducing the risk of contrast-induced kidney complications in certain patients, enhancing patient safety.
- Market Potential: As a diversified medical technology company, Abbott's extensive portfolio in diagnostics, medical devices, and nutritional products positions it strongly in the rapidly evolving healthcare market, especially as AI technologies become increasingly prevalent.
See More
Abbott Launches First Dual Glucose-Ketone Monitoring Biowearable
- Innovative Monitoring Technology: Abbott's Libre Duo system has received CE Mark approval, marking the first dual glucose-ketone monitoring technology that provides real-time data updates every minute, aiding diabetes patients in better health management and reducing the risk of diabetic ketoacidosis (DKA).
- Market Demand Response: Designed for both adults and children, the Libre Duo offers up to 15 days of wear, while the Libre Duo 10 Day is suitable for children aged 2 and older, addressing the needs of various age groups and significantly enhancing market competitiveness.
- Integration with Digital Health Ecosystem: The Libre Duo system seamlessly integrates with Abbott's digital health ecosystem, allowing users to share data with caregivers, enhancing interaction between patients and healthcare providers, and improving overall care quality.
- Addressing Rising DKA Issues: Research indicates that DKA hospitalization rates have increased by approximately 55% over the past decade, and the launch of the Libre Duo system aims to help patients take timely action through early ketone monitoring, thereby reducing DKA incidence and improving diabetes management outcomes.
See More
Abbott Launches New Colorectal Cancer Screening Solutions
- Guideline Update: The American Cancer Society's updated colorectal cancer screening guidelines reaffirm Cologuard® and Cologuard Plus® as preferred noninvasive options for adults aged 45 and older at average risk, which is expected to drive increased screening participation and improve early detection rates.
- Outstanding Detection Performance: Cologuard Plus detects 95% of colorectal cancers with 94% specificity in the U.S. screening population, significantly reducing unnecessary follow-up colonoscopies and enhancing patient confidence in screening results, which may lead to better treatment outcomes.
- Market Expansion Potential: Abbott plans to launch a blood-based test pending FDA approval, aimed at attracting individuals who decline other screening methods, thereby expanding the reach of colorectal cancer screening and further solidifying its market position in noninvasive screening.
- Patient Navigation Support: Cologuard tests, supported by a robust patient navigation program, have achieved up to 77% nationwide colorectal cancer screening participation, driving significant growth from 2018 to 2021, highlighting their strategic importance in improving patient screening experiences and outcomes.
See More
American Cancer Society Updates Colorectal Cancer Screening Guidelines
- Guideline Update: The American Cancer Society (ACS) has updated its colorectal cancer (CRC) screening guidelines, reaffirming Cologuard® and Cologuard Plus® as preferred noninvasive screening options for adults aged 45 and older at average risk, which is expected to drive increased screening participation and improve early detection and cure rates.
- Outstanding Test Performance: Cologuard Plus detects 95% of colorectal cancers with 94% specificity in the U.S. screening population, significantly reducing unnecessary follow-up colonoscopies and enhancing confidence among patients and providers, thereby promoting wider adoption of screening.
- Market Expansion Potential: Abbott plans to launch a blood-based test pending FDA approval, complementing its existing Cologuard portfolio to create a comprehensive CRC screening solution aimed at attracting individuals who decline other screening methods, thus expanding market coverage and increasing screening participation.
- Patient Navigation Support: Abbott's well-established patient navigation support and commercial infrastructure will ensure the reliability and seamless experience of the Cologuard products, which is expected to further enhance patient adherence to screening and satisfaction, contributing to lower incidence and mortality rates of colorectal cancer.
See More
Warren Buffett's Long-Term Investment Advice
- AbbVie's Strong Growth: AbbVie (ABBV), a leading pharmaceutical company, boasts multiple blockbuster drugs and strong growth potential, particularly with its autoimmune drugs Skyrizi and Rinvoq, which are expected to drive sustained growth over the next decade; despite Humira losing patent protection, the company has maintained stability through R&D investments and strategic acquisitions.
- Enterprise Products Partners' Stable Returns: Enterprise Products Partners (EPD) is a key player in the North American midstream energy market, operating over 50,000 miles of pipelines with a distribution yield of 5.5%, having increased its distribution for 27 consecutive years, demonstrating resilience and stability in a volatile energy sector.
- NextEra Energy's Renewable Leadership: NextEra Energy (NEE), the largest utility company globally, anticipates a 10% dividend increase this year, aiming for an 8% annual growth in adjusted earnings per share by 2035, showcasing its strong potential in renewable energy and battery storage.
- AI-Driven Market Opportunities: Both Enterprise Products Partners and NextEra Energy are poised to benefit from the increasing demand for natural gas and renewable energy driven by the growing need for power in data centers, with NextEra's planned $66.8 billion acquisition of Dominion Energy further solidifying its position in rapidly expanding markets.
See More
AbbVie and Two Dividend Kings Show Strong Prospects
- AbbVie's Growth Potential: AbbVie (NYSE: ABBV), a leading pharmaceutical company, boasts multiple blockbuster drugs and has around 60 programs in mid-to-late stage clinical trials, indicating strong growth prospects over the next decade, particularly with its autoimmune disease drugs Skyrizi and Rinvoq.
- Enterprise Products Partners' Stable Returns: Enterprise Products Partners (NYSE: EPD) is a top player in the North American midstream energy market, operating over 50,000 miles of pipelines with a distribution yield of 5.5%, having increased its distribution for 27 consecutive years, showcasing robust cash flow resilience and expected growth from rising natural gas demand.
- NextEra Energy's Acquisition Plans: As the largest utility company globally, NextEra Energy (NYSE: NEE) plans to acquire Dominion Energy for approximately $66.8 billion, which is expected to strengthen its leadership in renewable energy and battery storage, with dividends projected to grow by about 10% this year.
- AI-Driven Market Opportunities: With the increasing demand for power from data centers, both AbbVie and Enterprise Products Partners are poised to benefit from the AI technology boom, which is expected to drive business growth and enhance their competitive positions in the market.
See More
